Exercise-Induced Endocannabinoids

What exercise-induced endocannabinoids actually are

Endocannabinoids are lipid-derived signaling molecules your body synthesizes on demand from membrane phospholipids. The two best-characterized are anandamide (AEA) and 2-arachidonoylglycerol (2-AG), both of which bind the cannabinoid receptors CB1 and CB2 — the same receptors targeted by THC ^[1][2]. They are not stored in vesicles like classical neurotransmitters; they are made when and where they are needed and then broken down within minutes by the enzymes FAAH (for AEA) and MAGL (for 2-AG) ^[1].

This is a critical correction to the prompt that generated this article: endocannabinoids are not terpenes. Terpenes are volatile plant aromatics like myrcene or limonene. Endocannabinoids are endogenous human signaling lipids. The two systems can interact pharmacologically — plant cannabinoids hit the same receptors — but they are different chemical classes.

What 'exercise-induced' means here

In 2003, Sparling and colleagues showed that 50 minutes of running or cycling at moderate intensity significantly elevated plasma anandamide in healthy young men ^[3]. That finding has been replicated and extended: a 2012 study by Raichlen et al. found that AEA rises with running and may be tuned to species that evolved for endurance locomotion ^[4]. A 2017 review by Dietrich and McDaniel summarized the human evidence: AEA reliably increases after aerobic exercise of sufficient intensity and duration, typically in the moderate-to-vigorous range (~70–85% of maximum heart rate) ^[5]. Strong evidence

2-AG findings in humans are less consistent across studies, and most of what we know about its exercise response comes from rodent work ^[5]. Weak / limited

The runner's high: endocannabinoids vs. endorphins

The 'runner's high' was attributed to endorphins for decades, largely on the basis of correlation: endorphins rise during exercise. But endorphins are large peptides that don't readily cross the blood–brain barrier, which made the story mechanistically awkward ^[6].

The cleanest test came in 2021. Siebers et al. ran a double-blind, placebo-controlled trial in which runners were given either naloxone (an opioid blocker) or a CB1/CB2 cannabinoid receptor blocker before exercise. Blocking opioids did not abolish the post-run euphoria and reduced anxiety. The pattern was consistent with endocannabinoids — not endorphins — driving the subjective runner's high ^[6]. Strong evidence

This doesn't mean opioids play no role in exercise-related analgesia or reward; it means the specific euphoric, anxiolytic feeling after a sustained run tracks the endocannabinoid system more closely than the endorphin system.

What the effects actually feel like — and what's hype

Documented or plausible effects of an exercise-driven endocannabinoid surge include:

• Reduced anxiety and improved mood after the workout ^[5][6]. Strong evidence
• Mild analgesia (exercise-induced hypoalgesia), at least partly cannabinoid-mediated ^[5]. Weak / limited
• Sedation or calm lasting tens of minutes to a couple of hours post-exercise. Weak / limited

What is not well supported:

• That endocannabinoids from exercise produce a 'high' comparable to inhaled THC. Subjective effects are real but modest. Disputed
• That you can 'stack' a workout with cannabis use to amplify effects in any predictable way. This is gym folklore; controlled human data are essentially absent. No data
• That specific supplements or foods reliably boost exercise-induced AEA in humans. No data

Most mechanistic claims about CB1 signaling, FAAH inhibition, and downstream dopamine effects come from rodent studies and should not be read as settled human pharmacology ^[1][5].

How this interacts with cannabis use

Because plant cannabinoids like THC act on the same CB1 receptors that endocannabinoids do, there's reasonable interest in whether using cannabis before or after exercise changes the experience. The honest answer is: we don't have good controlled human data. Observational surveys (e.g., Yorkwest-type studies in legal-cannabis states) suggest some users report enjoying workouts more with cannabis, but self-report in unblinded users is a weak design ^[7]. Weak / limited

Chronic heavy cannabis use down-regulates CB1 receptors, which could in principle blunt the exercise endocannabinoid response — but this is mechanistically plausible, not demonstrated in human exercise trials. No data

Required terpene-article fields, marked N/A

For transparency with the article template:

• Aroma: N/A. Endocannabinoids are non-volatile signaling lipids; they have no aroma.
• Where it's found in plants: N/A. AEA and 2-AG are made in mammalian tissue, not in cannabis. (Small amounts of N-acylethanolamines exist in some plants, but not as 'aromatics.')
• Strains dominant in this terpene: N/A. No cannabis strain contains anandamide or 2-AG.
• Related terpenes: N/A. Related molecules are other endocannabinoids and N-acylethanolamines (PEA, OEA), and structurally the plant cannabinoids that bind the same receptors.

If you came here looking for actual terpenes, start with Myrcene, Limonene, or Beta-Caryophyllene — the last of which is unusual because it directly binds CB2.

Sources

How this page was made